Drug intelligence / Profile preview

Ro 67-7476

Development stage
Preclinical
Lead developer
Roche
Modality
Small Molecules
Administration
Subcutaneous
01

Overview

Ro 67-7476 is a potent and selective small molecule agonist of the metabotropic glutamate receptor 2 (mGlu2). Developed by Roche, it is primarily utilized as a pharmacological research tool to investigate glutamatergic neurotransmission and its role in central nervous system disorders such as schizophrenia, anxiety, and drug addiction. Activation of the mGlu2 receptor by Ro 67-7476 can trigger downstream signaling pathways, notably the extracellular signal-regulated kinase (ERK) pathway. In the context of oncology research, specifically in non-small-cell lung cancer (NSCLC) models, Ro 67-7476 has been used to induce ERK phosphorylation (p-ERK), effectively acting as a functional agonist of the ERK/MCL-1 pathway to study mechanisms of drug resistance and cell survival against chemotherapeutic agents like paclitaxel.

02

Targets

GRM1 (Metabotropic glutamate receptor 1)GRM2 (mGluR2)

Beyond the preview

Go deeper on Ro 67-7476.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ro 67-7476.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call